Interestingly, the 2021 study by Zhong and colleagues consisted of a randomized phase two trial (n=222) with EGFR mutation-positive NSCLC with resected stage II-IIIA to evaluate the effects of G treatment in comparison to vinorelbine plus cisplatin (VP). This evidence concerns the gene EGFR and non-small cell lung carcinoma.